康方生物(09926.HK)与中生制药(01177.HK)共研药物派安普利单抗拥有良好疗效
康方生物(09926.HK)公布,公司与中生制药(01177.HK)共同开发的PD-1单抗药物派安普利单抗(安尼可)(研发代号:AK105)治疗二线及以上已接受化疗治疗的转移性鼻咽癌的安全性及有效性数据在第35届肿瘤免疫治疗学会年会(「SITC 2020」)上以突破性成果(Late Breaking Abstract)形式发布,标题为《PD-1单抗派安普利在二线及以上已接受化疗治疗的转移性鼻咽癌患者中开展的单臂、开放、多中心II期临床研究》。
研究显示了派安普利治疗NPC拥有良好的疗效,还显示派安普利治疗NPC拥有良好的安全性,3级或以上药物相关不良事件(TRAE)发生率为15.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.